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Abstract: Erythromycin A is an established anti-bacterial agent against Gram-positive bacteria, but
it is unstable to acid. This led to an evaluation of erythromycin B and its derivatives because these
have improved acid stability. These compounds were investigated for their anti-malarial activities,
by their in silico molecular docking into segments of the exit tunnel of the apicoplast ribosome from
Plasmodium falciparum. This is believed to be the target of the erythromycin A derivative, azithromycin,
which has mild anti-malarial activity. The erythromycin B derivatives were evaluated on the multi-
drug (chloroquine, pyrimethamine, and sulfadoxine)-resistant strain K1 of P. falciparum for asexual
growth inhibition on asynchronous culture. The erythromycin B derivatives were identified as active
in vitro inhibitors of asexual growth of P. falciparum with low micro-molar IC50 values after a 72 h
cycle. 5-Desosaminyl erythronolide B ethyl succinate showed low IC50 of 68.6 µM, d-erythromycin B
86.8 µM, and erythromycin B 9-oxime 146.0 µM on the multi-drug-resistant K1 of P. falciparum. Based
on the molecular docking, it seems that a small number of favourable interactions or the presence of
unfavourable interactions of investigated derivatives of erythromycin B with in silico constructed
segment from the exit tunnel from the apicoplast of P. falciparum is the reason for their weak in vitro
anti-malarial activities.
Keywords: erythromycin B derivatives; anti-malarial activity; conformational search; molecular
docking; interactions
1. Introduction
Malaria remains a huge health problem worldwide with 229 million cases and
409,000 registered deaths reported in 2019 [1]. Due to the growing resistance from Southeast
Asia to Africa to almost all anti-malarial drugs, it is clear that new therapeutic strategies
are essential. Compounds like reversal agents (chemosentisizers, modulating agents) can
restore the sensitivity in resistant cells [2,3]. Erythromycin A was first discovered as a
reversal agent in multidrug-resistant cancer [4,5]. Antibiotics were found to possess anti-
plasmodial activity as early as 1940, but they were shown to be less effective and slow
acting compared to chloroquine or quinine [3]. Erythromycin A possesses in vitro and
in vivo anti-malarial activity [6]. Its anti-malarial action is improved in combination with
chloroquine; therefore, its modulating effect is important in chloroquine resistance [3].
Anti-malarial activity has been described for other antibiotics such as co-trimoxazole,
quinolones, tigecycline, mirincamycin, ketolides, fusidic acid, and thiopeptides [7]. Based
on studies in Africa, co-trimoxazole can be used as an alternative in malaria prophylaxis, for
children and adults, HIV (human immunodeficiency viruses) positive or negative patients
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and pregnant women [8–11]. Tigecycline must be administered intravenously; therefore,
its use is reserved for patients with severe and complicated malaria, with delayed action
similar to doxycycline [7].
The search for more active anti-malarial macrolides than the commercially available
anti-malarial drugs has continued. A research group at GSK (GlaxoSmithKline) in Zagreb
working on macrolides has published a series of ureas and thioureas of 15-membered
azalides with the ureas containing a naphthyl moiety being the most active and 9a-N
substituted 15-membered azalides with amide and amine functional groups with improved
in vivo efficacy [12,13].
Azithromycin was shown to be a slow anti-malarial targeting parasite apicoplast
(an organelle with four membranes containing 35 kb circular DNA (deoxyribonucleic
acid) with replication, RNA (ribonucleic acid) transcription, and RNA-protein translation
allowed [14]), giving IC50 in the nanomolar range [15], but better in combination with
existing anti-malarial drugs [16].
Therefore, developing a more effective and safer anti-malarial from the class of
macrolides is the aim of this research. Here, the in vitro anti-malarial activity of synthe-
sised derivatives of erythromycin B (erythromycin B 9-oxime, 5-desosaminyl erythronolide
B ethyl succinate, erythromycin B 2′-[3-(morpholinomethyl)benzoate], erythromycin B
2′-[3-(dimethylaminomethyl)benzoate], and 8-d-erythromycin B) (Figure 1), an acid-stable
derivative of erythromycin A [17] have been investigated, including the use of molecular
docking to give insight regarding the mechanism of action.
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2. Materials and Methods
2.1. Instrumentation
2.1.1. NMR (Nuclear Magnetic Resonance) Spectrometers
Bruker Avance 300 Spectrometer
A Bruker Avance 300 spectrometer (Bruker, Billerica, MA, USA) was operated with an
Oxford Instruments magnet (Billerica, MA, USA, magnetic field—7.04 Tesla). In this field,
the 1H resonated at 300 MHz and the 13C at 75.47 MHz. A 5 mm QNP (Quattro Nucleus
Probe–1H, 13C, 19F, 31P) probe with Z gradients was used.
Varian Unity 500 Spectrometer
A Varian Unity 500 NMR spectrometer (Varian Medical Systems, Palo Alto, CA, USA)
was operated with an Oxford Instruments magnet, magnetic field—11.74 Tesla. In this
field, the 1H resonated at 500 MHz. A 5 mm PFG (Pulse Field Gradient) probe was used.
The temperature was controlled using the Varian VT unit with a precision of ±0.1 ◦C.
Bruker AMX 500 Spectrometer
A Bruker AMX 500 (Bruker, Billerica, MA, USA) was operated with an Oxford Instru-
ments magnet, magnetic field—11.74 Tesla. Either a TXI-Z (triple nucleus inverse probe
with Z gradients) or a BBI (broad band inverse probe) was used.
The variable temperature unit was used as required. NMR tubes, 507-PP (Wilmad, NJ,
USA) were used in all experiments, unless otherwise stated. The spectrometers were used
to acquire one-dimensional (1H, 13C, DEPT (Distortionless Enhancement by Polarisation
Transfer)-45, DEPT-90 and DEPT-135) and two-dimensional (DQF-COSY, TOCSY, DOSY,
HMQC, and HMBC) spectra. The spectra were either acquired in deuterated chloroform
(CDCl3) referenced to tetramethylsilane (TMS) (Lancaster, UK) as an internal standard or
in deuterated buffer (apparent pH 2.0, 6.0, and 7.0) referenced to 3-(trimethylsilyl)-2,2,3,3-
tetradeuterio-propionic acid sodium salt (TSP) (Aldrich, Gillingham UK).
2.1.2. Mass Spectrometer
Electrospray ionisation-mass spectra (ESI-MS) were acquired on a Micromass Platform
mass spectrometer (Waters Corporation, Milford, MA, USA), and the data were analysed
using the program PLATFORM with a Masslynx data system. The sample (10 µL) was
injected using a Hewlett Packard auto-sampler, and the machine was operated at a cone
value of 30 eV, at 80 ◦C. For identification purposes, all samples (0.2 mg) were prepared
in acetonitrile (1 mL). For degradation studies, a deuterated Britton–Robinson buffer was
used unless otherwise stated. Water was used as the solvent for running the samples unless
otherwise stated.
2.1.3. pH Meter
All pH measurements were carried out using a Mettler Delta 320 (Mettler Toledo,
Greifensee, Switzerland), equipped with a combination electrode (Gelpas, BDH, Poole, UK).
The pH of the deuterated buffers was measured on the Hanna pH 213 (Hanna Instruments
Inc., Woonsocket, RI, USA), equipped with a combination electrode (Gelpas, BDH, Poole,
UK) and a temperature probe. Buffer reference standards (4.00 ± 0.01, 7.00 ± 0.01, and
10.00 ± 0.01 at 25 ◦C) (Sigma-Aldrich, Saint Louis, MO, USA) were used to calibrate the pH
meters by a two-point calibration method. All pH measurements were at room temperature
and are reported uncorrected.
2.1.4. Melting Point Apparatus
All melting points were determined using a Bibby SMP-10 (Stuart Scientific, Stafford-
shire, UK) melting point apparatus and are reported uncorrected. The samples were placed
in a capillary tube and inserted in the melting point apparatus and were heated at a rate of
1 ◦C/min until the compound melted.
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2.1.5. Thin Layer Chromatography (TLC)
All the TLC experiments were carried on already-prepared aluminium-backed silica
gel 60 F254 (Merck, Darmstadt, Germany) plates without any prior activation. Spots were
applied using a 5 µL capillary, and EtOAc-CH3OH-25% NH3 (85:10:5) was used as the
mobile phase [18]. The plates were dried in the oven for 1 min and then were sprayed with
p-anisaldehyde: sulphuric acid: ethanol mixture (1:1:9). The plates were dried in the oven
set at 110 ◦C for 5 min, and the Rf value for each of the compounds was determined.
2.2. Two-Dimensional NMR Spectroscopy
2.2.1. TOCSY and DQF-COSY
For structural determination, both the TOCSY (Total Correlated Spectroscopy) and the
DQF-COSY (Double Quantum Filtered Correlated Spectroscopy) spectra were obtained
at ambient temperature on the Varian Unity 500 spectrometer. In the TOCSY experiment,
cross-peaks were found for all the protons in the same spin system. The COSY spectrum
indicated all the spin–spin coupled protons. For both the experiments, 2048× 2048 complex
points were acquired. The spectra were processed using negative line broadening and
Gaussian multiplication for resolution enhancement.
2.2.2. HMQC and HMBC
HMBC (Heteronuclear Multiple Bond Connectivity) and HMQC (Heteronuclear Mul-
tiple Quantum Coherence) spectra were acquired on the Varian Unity 500 spectrometer. An
HMBC spectrum was acquired by using a long-range 1H-13C COSY pulse sequence to give
a two-dimensional spectrum with 13C chemical shifts on one axis and 1H chemical shifts
on the other. An HMQC indicated single-bond correlation between 13C and the proton to
which, it was directly attached.
2.2.3. DOSY
Erythromycin B 2′-ethyl succinate was dissolved in deuterated Britton–Robinson
buffer at an apparent pH 2.0 to give concentration of 4 mM and was degraded over two
hours. The degraded samples were cooled to ambient temperature and a high resolution
DOSY (Diffusion-Ordered Spectroscopy) spectrum was acquired using a ONESHOT DOSY
pulse sequence. Twelve spectra were acquired, with gradient pulses of 2.9 ms. The FIDDLE
(free induction decay deconvolution for line shape enhancement) algorithm [19] was used
to correct line shapes using TSP as a reference standard. DOSY spectra were constructed
after baseline correction by taking the first echo spectrum and distributing the intensities
of the individual signals in the second dimension according to their respective diffusion
coefficient [20,21].
2.3. Synthesis of Erythromycin B Derivatives
Erythromycin B was a gift from Dr. Warren Mann, Abbott International Division,
which was used without further purification. Acetone (GPR grade, BDH, Poole, UK)
dried over anhydrous sodium sulphate (Na2SO4) was used as a solvent in most syntheses,
unless stated otherwise. The water work-up refers to washing the organic layer with water
(2 × 50 mL) and 50 mL brine (saturated sodium chloride solution).
2.3.1. Synthesis of Erythromycin B Oxime
The First Method
This method was adapted from Gasc et al. (1991) [22]. Erythromycin B (5.0 g) was dis-
solved in 50 mL methanol (GPR grade, BDH, UK, previously dried over sodium sulphate)
followed by addition of 2.46 mL triethylamine and 2.46 g hydroxylamine hydrochloride
(Sigma-Aldrich, Burlington, MA, USA). The mixture was refluxed for 24 h. After complete
dissolution, the progressive crystallisation of erythromycin B oxime hydrochloride was
observed. The reaction mixture was cooled to 2 ◦C for 1 h. The crystals were separated
and washed three times with 2.5 mL cooled methanol. To the suspension of erythromycin
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oxime hydrochloride in 15 mL methanol (20 ◦C), 3.26 mL of ammonium hydroxide solution
(20%) was added. After stirring for 30 min, 3.26 mL of water was added to the solution
to give 1.8 g of erythromycin B oxime. Yield 36.0%, m.p. 170–174 ◦C, 1H NMR (CDCl3,
300 MHz): δ 0.87 (CH3-21, d, J = 7.1 Hz), δ 0.87 (CH3-15, t, J = 7.3 Hz), δ 1.05 (CH3-20, d,
J = 6.8 Hz), δ 1.12 (CH3-17, d, J = 7.5 Hz), δ 1.13 (CH3-19, d, J = 7.1 Hz), δ 1.18 (CH3-16, d,
J = 7.3 Hz), δ 1.21 (CH3-6′, d, J = 6.0 Hz), δ 1.21 (CH3-7”, s), δ 1.29 (CH3-6”, d, J = 6.2 Hz),
δ 1.5 (CH3-18, s), δ 2.28 (N(CH3)2-7′,8′, s), δ 2.89 (CH-2, dq, J = 9.0, 7.1 Hz), δ 3.21 (CH-2′,
dd, J = 10.3, 7.5 Hz), δ 3.31 (OCH3-8”, s), δ 3.49 (CH-5′, m), δ 3.6 (CH-5, d, J = 7.5 Hz),
δ 3.63 (CH-11, d, J = 10.0 Hz), δ 4.0 (CH-5”, dq, J = 9.5, 6.2 Hz), δ 4.06 (CH-3, dd, J = 9.0,
1.5 Hz), δ 4.43 (CH-1′, d, J = 7.3 Hz), δ 4.93 (CH-1”, d, J = 4.7 Hz), δ 5.42 (CH-13, dd, J = 9.6,
4.6 Hz); m/z 733 [M + H]+; Rf 0.36 (CH2Cl2-CH3OH-25% NH3, 90:9:1.5) [18]; Anal. Calcd
for C37H68N2O12 (%): C 60.62, H 9.37, N 3.82. Found (%): C 60.42, H 9.29, N 3.71.
The Second Method
This method was adapted from Watanabe et al. (1993) [23]. Erythromycin B (5.0 g),
2.49 g anhydrous sodium acetate (Fisher Scientific, Loughborough, UK) and 1.75 g hy-
droxylamine hydrochloride (Sigma-Aldrich, Burlington, MA, USA) were added to 20
mL methanol, and the suspension was stirred at room temperature for 6 days and then
refluxed for 30 min. The reaction mixture was concentrated in vacuo to about half the
original volume and poured into 10 mL water. The resulting crystals were filtered, tritu-
rated successively with water, saturated NaHCO3 solution and water, and then filtered.
Crystallisation from dichloromethane-n-hexane gave 3.46 g of erythromycin B oxime. Yield
69.2%, m.p. 172–174 ◦C, 1H NMR (CDCl3, 500 MHz): δ 0.89 (CH3-21, d, J = 7.1 Hz), δ 0.88
(CH3-15, t, J = 7.3 Hz), δ 1.03 (CH3-20, d, J = 6.8 Hz), δ 1.03 (CH3-16, d, J = 7.3 Hz), δ 1.12
(CH3-17, d, J = 7.5 Hz), δ 1.18 (CH3-19, d, J = 7.1 Hz), δ 1.25 (CH3-6′, d, J = 6.0 Hz), δ 1.25
(CH3-7”, s), δ 1.32 (CH3-6”, d, J = 6.2 Hz), δ 1.51 (CH3-18, s), δ 2.27 (N(CH3)2-7′,8′, s), δ 2.89
(CH-2, dq, J = 9.0, 7.1 Hz), δ 3.0 (CH-10, dq, J = 6.8, 1.1 Hz), δ 3.23 (CH-2′, dd, J = 10.3,
7.5 Hz), δ 3.33 (OCH3-8”, s), δ 3.49 (CH-5′, m), δ 3.58 (CH-5, d, J = 7.5 Hz), δ 3.59 (CH-11,
bd, J = 10.0 Hz), δ 4.0 (CH-5”, dq, J = 9.5, 6.2 Hz), δ 4.06 (CH-3, dd, J = 9.0, 1.5 Hz), δ 4.42
(CH-1′, d, J = 7.3 Hz), δ 4.92 (CH-1”, d, J = 4.7 Hz), δ 5.42 (CH-13, dd, J = 9.6, 4.6 Hz); m/z
733 [M+H]+; Rf 0.23 (CH2Cl2-CH3OH-25% NH3, 90:9:1.5); Anal. Calcd for C37H68N2O12
(%): C 60.62, H 9.37, N 3.82. Found (%): C 60.51, H 9.63, N 3.66.
2.3.2. Synthesis of Erythromycin B 2′-(3-chloromethylbenzoate) (EBCMB)
EBCMB acts as a starting material for all the erythromycin 2′-(N-substituted 3- or 4-
aminomethylbenzoate) esters. It was prepared by adapting the procedure used by Jensen
et al. (1990) [24]. 3-Chloromethylbenzoyl chloride (1.25 mL, Sigma-Aldrich, Burlington,
MA, USA) in 5 mL acetone was added dropwise to a mixture of erythromycin B (5 g) and
1 g NaHCO3 in 200 mL acetone. The resulting solution was stirred at room temperature
overnight. The residue was stirred with 100 mL phosphate buffer (pH 6.5) for 15 min
followed by a water work-up. The organic layer was dried in vacuo, and the crystalline
product was recrystallised from ethyl acetate. Yield 89.4%, m.p. 192–194 ◦C, 1H NMR
(CDCl3, 500 MHz): δ 0.72 (CH3-17, d, J = 7.1 Hz), δ 0.76 (CH3-21, d, J = 7.5 Hz), δ 0.82
(CH3-15, t, J = 7.4 Hz), δ 0.96 (CH3-20, d, J = 6.8 Hz), δ 1.12 (CH3-19, d, J = 7.1 Hz), δ 1.16
(CH3-16, d, J = 7.1 Hz), δ 1.26 (CH3-6′, d, J = 6.2 Hz), δ 1.27 (CH3-7”, s), δ 1.29 (CH3-6”, d,
J = 6.2 Hz), δ 1.46 (CH3-18, s), δ 2.25 (N(CH3)2-7′,8′, s), δ 2.36 (CH-2”, d, J = 15.2 Hz), δ 3.41
(OCH3-8”, s), δ 3.55 (CH-5, d, 7.5 Hz), δ 3.69 (CH-11, d, J = 9.8 Hz), δ 4.0 (CH-5”, obs),
δ 4.61 (CH2-16′, s), δ 4.70 (CH-1′, d, J = 7.5 Hz), δ 4.86 (CH-1”, d, J = 4.5 Hz), δ 5.02 (CH-2′,
dd, J = 10.5, 7.5 Hz), δ 5.28 (CH-13, dd, J = 9.4, 4.8 Hz), δ 7.42 (CH-12′, dd, J = 7.7 Hz), δ 7.57
(CH-13′, d, J = 7.7 Hz), δ 7.96 (CH-11′, d, J = 7.7 Hz), δ 8.05 (CH-15′, s); m/z 870 [M + H]+;
Rf 0.62 (EtOAc-CH3OH-25% NH3, 85:10:5); Anal. Calcd for C45H72NO13Cl (%): C 62.08,
H 8.35, N 1.60. Found (%): C 62.05, H 8.40, N 1.59.
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2.3.3. Synthesis of Erythromycin B 2′-[3-(morpholinomethyl)benzoate] (EBMMB)
A mixture of erythromycin B 2′-(3-chloromethylbenzoate) (1 g), morpholine (0.2 mL)
and sodium iodide (20 mg) in 75 mL acetone was refluxed for 20 h. Following the water
work-up the organic layer was reduced to dryness in vacuo. The colourless crystals of
EBMMB were recrystallised from ethyl acetate. Yield 83%, m.p. 126–128 ◦C, 1H NMR
(CDCl3, 500 MHz): δ 0.7 (CH3-17, d, J = 7.1 Hz), δ 0.76 (CH3-21, d, J = 7.5 Hz), δ 0.84
(CH3-15, t, J = 7.4 Hz), δ 0.96 (CH3-20, d, J = 6.8 Hz), δ 1.13 (CH3-19, d, J = 7.3 Hz), δ 1.17
(CH3-16, d, J = 6.8 Hz), δ 1.26 (CH3-6′, d, J = 6.2 Hz), δ 1.28 (CH3-7”, s), δ 1.30 (CH3-6”, d,
J = 6.2 Hz), δ 1.46 (CH3-18, s), δ 2.26 (N(CH3)2-7′,8′, s), δ 3.42 (OCH3-8”, s), δ 3.49 (CH-5′,
m), δ 3.58 (CH-5, d, J = 7.5 Hz), δ 3.69 (CH-11, d, J = 10.0 Hz), δ 4.0 (CH-5”, dq, J = 9.4,
6.2 Hz), δ 4.0 (CH-3, dd, J = 9.0, 1.5 Hz), δ 4.70 (CH-1′, d, J = 7.5 Hz), δ 4.87 (CH-1”, d,
J = 4.9 Hz), δ 5.04 (CH-2′, dd, J = 10.5, 7.5 Hz), δ 5.29 (CH-13, dd, J = 9.2, 4.3 Hz), δ 7.37
(CH-12′, dd, J = 7.7 Hz), δ 7.54 (CH-13′, d, J = 7.7 Hz), δ 7.90 (CH-11′, d, J = 7.7 Hz), δ 7.94
(CH-15′, s); m/z 921 [M + H]+; Rf 0.61 (EtOAc-CH3OH-25% NH3, 85:10:5); Anal. Calcd for
C49H80N2O14 (%): C 64.02, H 8.79, N 4.57. Found (%): C 63.84, H 8.71, N 4.51.
2.3.4. Synthesis of Erythromycin B 2′-[3-(dimethylaminomethyl)benzoate] (EBDMAMB)
A mixture of erythromycin B 2′-(3-chloromethylbenzoate) (2 g), dimethylamine (3.9 mL
of a 33% solution in ethanol) (Fluka, Loughborough, UK), and sodium iodide (20 mg) in
100 mL acetone (previously dried over anhydrous Na2SO4) was refluxed for 20 h. Follow-
ing the water work-up, the organic layer was reduced to dryness in vacuo, and the colourless
crystals of EBDMAMB were recrystallised from ethyl acetate. Yield 65%, m.p.128–130 ◦C,
1H NMR (CDCl3, 500 MHz): δ 0.71 (CH3-17, d, J = 7.1 Hz), δ 0.73 (CH3-21, d, J = 7.5 Hz),
δ 0.82 (CH3-15, t, J = 7.4 Hz), δ 0.96 (CH3-20, d, J = 6.8 Hz), δ 1.12 (CH3-19, d, J = 7.1 Hz),
δ 1.16 (CH3-16, d, J = 7.1 Hz), δ 1.26 (CH3-6′, d, J = 6.2 Hz), δ 1.27 (CH3-7”, s), δ 1.30 (CH3-6”,
d, J = 6.2 Hz), δ 1.46 (CH3-18, s), δ 2.26 (N(CH3)2-7′,8′, s), δ 3.05 (CH-4”, d, J = 9.2 Hz), δ 3.41
(OCH3-8”, s), δ 3.54 (CH-5, d, J = 7.5 Hz), δ 3.55 (CH-5′, m), δ 3.69 (CH-11, d, J = 9.6 Hz),
δ 3.98 (CH-3, dd, J = 9.0, 1.5 Hz), δ 4.0 (CH-5”, dq, J = 9.0, 6.2 Hz), δ 4.61 (CH-16′, s), δ 4.7
(CH-1′, d, J = 7.5 Hz), δ 4.87 (CH-1”, d, J = 4.5 Hz), δ 5.04 (CH-2′, dd, J = 10.5, 7.5 Hz), δ 5.28
(CH-13, dd, J = 9.4, 4.3 Hz), δ 7.39 (CH-12′, dd, J = 7.7 Hz), δ 7.54 (CH-13′, bd, J = 7.6 Hz),
δ 7.91 (CH-11′, d, J = 7.6 Hz), δ 7.96 (CH-15′, s); m/z 879 [M + H]+; Rf 0.3 (EtOAc-CH3OH-
25% NH3, 85:10:5); Anal. Calcd for C47H78N2O13 (%): C 64.20, H 8.96, N 3.18. Found (%):
C 64.49, H 8.98, N 3.19.
2.3.5. Synthesis of 5-Desosaminyl Erythronolide B Ethyl Succinate
5-Desosaminyl erythronolide B ethyl succinate was made from erythromycin B ethyl
succinate under similar conditions previously described [17,25,26].
2.3.6. Synthesis of Erythromycin B Enol Ether
Erythromycin B enol ether was made from erythromycin B under conditions previ-
ously described [25].
2.3.7. Synthesis of 8-d-erythromycin B (8D-EB)
8-d-erythromycin B was made from erythromycin B enol ether under conditions
previously described [27].
2.4. In Vitro Determination of the Anti-Malarial Activity of Selected Erythromycin B Derivatives
2.4.1. Cultivation of P. falciparum Parasite
Chloroquine, pyrimethamine and sulfadoxine-resistant K1 strain of P. falciparum was
cultured with RPMI (Roswell Park Memorial Institute) 1640 media containing 25 mM
(2-hydroxyethyl) piperazine-N’-(2-ethane-sulfonic acid) (HEPES) and 0.3 g/L L-glutamine
(Gibco, Life Technologies, Renfrew, UK). The medium was supplemented with sterile
filtered 2.5 g AlbuMax (Sigma-Aldrich, Saint Louis, MO, USA), 2.5 mL hypoxanthine
(Sigma-Aldrich, Saint Louis, MO, USA), 2.5 mL 40% glucose (Dextrose Anhydrous, Fisher
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Scientific, UK) and 0.5 mL gentamycin (Sigma-Aldrich, Saint Louis, MO, USA). Human
erythrocytes served as host cells. Cultures were maintained at 37 ◦C under the gas mixture
of 5% CO2 and 5% O2 in N2 gas mixture (BOC Limited, Guildford, UK).
2.4.2. Synchronisation of K1 P. falciparum
The K1 strain of P. falciparum was cultivated until ≥8% parasitaemia was obtained,
with neat prevalence of ring stages. The culture was then transferred to a falcon tube
and centrifuged at 3500 rpm for 5 min at 20 ◦C. Supernatant was removed, and the pellet
was re-suspended in 5 mL of aqueous 5% sorbitol at room temperature for 5 min and
further centrifuged as before. The supernatant was removed, and the pellet was washed
3 times with complete media before setting up a new culture. The pellet was re-suspended
in complete media with enough purified 50% RBCs (red blood cells) to obtain 5% final
haematocrit.
2.4.3. Determination of IC50 in K1 P. falciparum
Here, 1% infected RBCs with P. falciparum K1 strain at ring stage were exposed to
9 dilutions at concentrations of 3.05 nM–200 µM (4-fold serial dilution) of compounds from
50 mM stock solutions. 100 µL of culture volume was added in 96-well plates with 100 µL
drug dilutions. Untreated infected RBCs served as positive control while the uninfected
RBCs was a negative control. The plates were incubated for 72 h at 37 ◦C, 5% CO2, and 5%
O2 in N2. Following the incubation, 150 µL of media was carefully removed, and 150 µL of
SYBR (Synergy Brands) Green solution (prepared by adding 2 µL of 10,000 X SYBR Green
in 4 mL of phosphate buffer saline (PBS)) was added to each well. The plates were kept
in the dark for 45 min at room temperature. The fluorescence intensity was measured
using a microplate reader (Genius Tecan) set at 485 nm excitation and 535 nm emission
wavelengths. Chloroquine was included as a control drug.
The IC50 values were determined using Graph Pad Prism 5.0. Values were calculated
using non-linear regression by using log-transformed drug concentration plotted against
dose-response. Parasitaemia was calculated and normalised relative to response on the
controls (cultures without drug).
2.5. Conformational Search Studies
2.5.1. Unconstrained Conformational Search
Conformational analysis of selected derivatives of erythromycin B (erythromycin B
9-oxime, 5-desosaminyl erythronolide B ethyl succinate, erythromycin B 2′-[3-(morpholinome
thyl)benzoate], erythromycin B 2′-[3-(dimethylaminomethyl)benzoate], and 8-d-erythromycin
B) was performed using Macromodel under Schrodinger Suite 2021-1 and Maestro v. 12.7.156
as the interface. Chloroform was used as a solvent. The minimisations were first performed
with charges from force field, cut off was extended, minimisation method was TNCG (Trun-
cated Newton Conjugate Gradient), and the number of maximum iterations was set to 10,000,
with the gradient convergence, and its threshold 0.05. Conformational search torsional
sampling was MCMM (Monte Carlo multiple minimum) with automatic setup during the
calculation, and torsion sampling options: intermediate. The maximum number of steps was
10,000, with 100 steps per rotatable bond. Number of structures to be saved for each search
was 100, energy window for saving structures 21 kJ/mol, and maximum atom deviation cut
off 0.5 Å.
2.5.2. Constrained Conformational Search
The constrained conformational search was performed for erythromycin B 2′-[3-
(dimethylaminomethyl)benzoate] in chloroform using Macromodel and Maestro v. 12.7.156
as the interface under Schrodinger Suite 2021-1. The distance H4-H11 was constrained
to 2.5 ± 0.3 Å and H5-H18 to 2.5 ± 0.3 Å starting from the global minimum of the uncon-
strained conformational search for this compound.
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Conformational search torsional sampling was MCMM with automatic setup during
the calculation and torsion sampling options: intermediate. The maximum number of
steps was 10,000, with 100 steps per rotatable bond. Number of structures to be saved for
each search was 100, energy window for saving structures 21 kJ/mol, and maximum atom
deviation cut off 0.5 Å.
2.6. Molecular Docking Studies
Molecular docking studies were performed using the Patchdock web server with the
Patchdock molecular docking algorithm based on shape complementarity principles [28–30].
The input is set consisting of the pdb files of the receptor molecule and the ligand molecule.
The pdb files of the ligand molecules consisted of folded-out structures obtained in the
unconstrained conformational search for all investigated erythromycin B derivatives, except
erythromycin B 2′-[3-(dimethylaminomethyl)benzoate], where we used the global minimum
of the constrained conformational search. The output is a list of the potential complexes
sorted by the shape complementarity principles.
Ten best results from docking analysis using Patchdock algorithm were submitted to
FireDock for refinement [31,32].
Visualisation of the results and the formation of 2D diagrams were performed using
Discovery Studio 2021 Client (Dessault Systems Biovia Corp., San Diego, CA, USA).
3. Results and Discussion
3.1. Synthesis of N-Substituted 2′-(3-aminomethylbenzoate) Esters of Erythromycin B
N-substituted 2′-(3-aminomethylbenzoate) esters of erythromycin B were synthesised in
two steps. In the first step, erythromycin B was esterified at C-2′ with 3-chloromethylbenzoyl
chloride. In the second step, the product erythromycin B 2′-[3-chloromethylbenzoate] was
heated at reflux with the appropriate amine (R) in the presence of sodium iodide as a catalyst
(Scheme 1) [33].




Scheme 1. Synthesis of N-substituted 2′-(3-aminomethylbenzoate) esters from erythromycin B as a starting macrolide. 
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but they have never been investigated as anti-malarials. Due to the fact that erythromycin 
B possesses acid stability [17], we hypothesised that they would show better anti-malarial 
activity when compared with erythromycin A. Therefore, we selected several derivatives 
of erythromycin B for evaluation: erythromycin B 9-oxime, 5-desosaminyl erythronolide 
B ethyl succinate, erythromycin B 2′-[3-(morpholinomethyl)benzoate], erythromycin B 2′-
[3-(dimethylaminomethyl)benzoate], and 8-d-erythromycin B. 
A 1% parasitised culture at ring stage was treated with the compounds for 72 h at 
concentrations of 3.05 nM–200 μM (four-fold serial dilution) against the P. falciparum K1 
strain, and the growth was measured using the SYBR Green-based plate reader assay. 
SYBR Green is a sensitive DNA stain that can bind to the double-stranded parasite 
DNA, and once intercalated, it becomes fluorescent [34]. SYBR Green assay offers a quick, 
inexpensive, and straightforward method to test parasites’ susceptibility of anti-malarial 
drugs [35]. The assay takes the advantage of the fact that the parasite–host cells (healthy 
human mature erythrocytes) lack DNA; therefore, the fluorescence intensity reflects par-
asite growth. 
The investigated compounds exhibited anti-malarial activities with micromolar IC50 
values against the multi-drug-resistant P. falciparum strain K1 (Figure 2). Erythromycin B 
9-oxime gave an IC50 value of 146.0 μM; 5-desosaminyl erythronolide B ethyl succinate 
gave an IC50 value of 68.6 μM; and 8-d-erythromycin B gave an IC50 of 86.8 μM. Both eryth-
romycin B 2′-[3-(morpholinomethyl)benzoate] and erythromycin B 2′-[3-(dimethyla-
minomethyl)benzoate] were less active, with IC50 values of more than 200 μM. 
Scheme 1. Synthesis of N-substituted 2′-(3-aminomethylbenzoate) esters from erythromycin B as a starting macrolide.
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3.2. In Vitro Investigation of Synthesised Erythromycin B Derivatives against P. falciparum
K1 Strain
Erythromycin B and its derivatives were shown to possess anti-bacterial activity [17],
but they have never been investigated as anti-malarials. Due to the fact that erythromycin
B possesses acid stability [17], we hypothesised that they would show better anti-malarial
activity when compared with erythromycin A. Therefore, we selected several derivatives
of erythromycin B for evaluation: erythromycin B 9-oxime, 5-desosaminyl erythronolide
B ethyl succinate, erythromycin B 2′-[3-(morpholinomethyl)benzoate], erythromycin B
2′-[3-(dimethylaminomethyl)benzoate], and 8-d-erythromycin B.
A 1% parasitised culture at ring stage was treated with the compounds for 72 h at
concentrations of 3.05 nM–200 µM (four-fold serial dilution) against the P. falciparum K1
strain, and the growth was measured using the SYBR Green-based plate reader assay.
SYBR Green is a sensitive DNA stain that can bind to the double-stranded parasite
DNA, and once intercalated, it becomes fluorescent [34]. SYBR Green assay offers a quick,
inexpensive, and straightforward method to test parasites’ susceptibility of anti-malarial
drugs [35]. The assay takes the advantage of the fact that the parasite–host cells (healthy
human mature erythrocytes) lack DNA; therefore, the fluorescence intensity reflects parasite
growth.
The investigated compounds exhibited anti-malarial activities with micromolar IC50
values against the multi-drug-resistant P. falciparum strain K1 (Figure 2). Erythromycin B 9-
oxime gave an IC50 value of 146.0 µM; 5-desosaminyl erythronolide B ethyl succinate gave an
IC50 value of 68.6 µM; and 8-d-erythromycin B gave an IC50 of 86.8 µM. Both erythromycin B
2′-[3-(morpholinomethyl)benzoate] and erythromycin B 2′-[3-(dimethylaminomethyl)benzo
ate] were less active, with IC50 values of more than 200 µM.
3.3. Conformational Search Studies of the Investigated Derivatives of Erythromycin B
in Chloroform
3.3.1. Unconstrained Conformational Search of the Investigated Derivatives of
Erythromycin B in Chloroform
We chose chloroform as a solvent because it was previously found that the most
commonly used dielectric constant for proteins is 4; inside the protein according to the
recent investigation, it is 6–7 [36]; and inside nucleic acids, it is 2 [37].
Folded-out and folded-in terms were defined by Everett et al. (1990) [38], and it was
shown that erythromycin A mainly possesses characteristics of the folded-out conforma-
tional type [39]. The distances (Å) among the characteristic hydrogens for folded-out
and folded-in conformations were measured for selected derivatives of erythromycin B in
chloroform as a solvent, which are given in Table 1, together with the energies of global
minima and the number of times they repeat.
The global minimum of erythromycin 9-oxime in chloroform is neither folded out nor
folded in, although the H4-H18 and H3-H8 distances correspond to a typical folded-in
conformation. Erythromycin B 2′-[3-(morpholinomethyl) benzoate] in chloroform has a
global minimum, which is a variation of a folded-out conformation. The global minimum
of erythromycin B 2′-[3-(dimethylaminomethyl)benzoate] in chloroform is a typical folded-
in conformation. 5-Desosaminyl erythronolide B ethyl succinate in chloroform shows a
global minimum that is neither folded-out nor folded-in, but is different from the global
minimum of erythromycin B 2′-[3-(morpholinomethyl) benzoate]. The global minimum of
8-d-erythromycin B is a folded-in conformation.
Previously, it was shown that the active conformation of the macrolide antibiotics bound
weakly to bacterial ribosomes, such as clarithromycin, erythromycin A, and azithromycin [39],
is mainly the folded-out conformation. None of the global minima for the investigated
derivatives of erythromycin B is a typical folded-out conformation. Typical folded-out con-
formations for erythromycin B and 8-d-erythromycin B were found bound weakly to the
bacterial ribosomes [27]; therefore, folded-out conformations were used for the docking anal-
ysis as the active conformations of the ligands-investigated derivatives of erythromycin B
(erythromycin B 9-oxime, erythromycin B 2′-[3-(morpholinomethyl) benzoate], erythromycin
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B 2′-[3-(dimethylaminomethyl)benzoate], 5-desosaminyl erythronolide B ethyl succinate, and
8-d-erythromycin B) to the complex consisting of 23S rRNA and L4 protein from the apicoplast
ribosome of P. falciparum previously constructed in silico [40]. The typical folded-out confor-
mation (H4-H11 (2.37 Å), H5-H18 (2.58 Å), H15-H16 (2.92 Å)) of erythromycin B 9-oxime was
found with the energy 128.73 kJ/mol and erythromycin B 2′-[3-(morpholinomethyl) benzoate]
with the energy 103.57 kJ/mol (H4-H11 (2.77 Å), H5-H18 (2.54 Å), H15-H16 (3.05 Å)). Among
the first 50 conformations of the unconstrained conformational search of erythromycin B 2′-[3-
(dimethylaminomethyl)benzoate], the typical folded-out conformation was not found—the
most similar was found with the energy 71.84 kJ/mol (H4-H11 (2.60 Å), H5-H18 (3.47 Å), and
H15-H16 (4.54 Å)). 5-Desosaminyl erythronolide B ethyl succinate shows the typical folded-out
conformation with the energy 110.47 kJ/mol (H4-H11 (2.24 Å), H5-H18 (2.64 Å), H15-H16
(3.06 Å)), and 8-d-erythromycin B with the energy 112.5 kJ/mol (H4-H11 (2.82 Å), H5-H18
(2.61 Å), and H15-H16 (3.13 Å)).








Figure 2. Dose-response curves for (a) erythromycin B 9-oxime (EryB 90), (b) 5-desosaminyl erythronolide B ethyl succin-
ate (5DAEBES), (c) erythromycin B 2′-[3-(morpholinomethyl) benzoate] (EBMMB), (d) erythromycin B 2′-[3-(dimethyla-
minomethyl)benzoate] (EBDAMB), and (e) 8-d-erythromycin B (d-Ery B). 
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Figure 2. Dose-response curves for (a) erythro ycin B 9-oxime (EryB 90), (b) 5-desosaminyl erythronolide B ethyl
succinate (5DAEBES), (c) erythromycin B 2′-[3-(morpholinomethyl) benzoate] (EBMMB), (d) erythromycin B 2′-[3-
(dimethylaminomethyl)benzoate] (EBDAMB), and (e) 8-d-erythromycin B (d-Ery B).
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Table 1. Distances (Å) for the selected contacts of the global minima obtained in the unconstrained conformational search
for selected derivatives of erythromycin B, and energies of global minima and times they repeat.
Compounds






H4-H11 H15-H16 H3-H8 H3-H11 H4-H18 H5-H18 H16-H17












−118.56 1 3.82 3.05 6.93 4.72 3.55 3.44 4.99
8-d-Erythromycin B 111.13 1 3.97 3.76 2.35 * 2.19 2.73 3.47 2.26
* H3-D8.
3.3.2. Constrained Conformational Search of Erythromycin B
2′-[3-(dimethylaminomethyl)benzoate]
The constrained conformational search on erythromycin B 2′-[3-(dimethylaminomethyl)
benzoate] in chloroform gave a global minimum with the energy 69.02 kJ/mol repeated two
times. It is a folded-out structure (H4-H11 (2.79 Å), H5-H18 (2.54 Å), and H15-H16 (3.04 Å)).
3.4. Docking Analysis of the Investigated Derivatives of Erythromycin B into In Silico Constructed
Segment of the Exit Tunnel from the Apicoplast Ribosome of P. falciparum
The docking analysis of erythromycin B derivatives into in silico constructed exit
tunnel from apicoplast ribosome from P. falciparum was complex. The majority of free or
commercially available software for molecular docking are either suitable for proteins or
RNAs as receptors, but not for complexes which contain both protein and RNA residues.
We chose PatchDock for our docking analysis because it relies on different principles—on
shape complementarity [26–28]—compared to other software.
For all docking analyses with derivatives of erythromycin B as ligands and complexes
containing protein and three domains of 23S rRNAs as receptors, results were characterised
with the parameters presented in Table 2, such as score, area, and ACE.
Ten best results of performed molecular docking for each investigated erythromycin
B derivatives were subjected to FireDock refinement. Solution number, global energy,
attractive van der Waals, repulsive van der Waals, and ACE for investigated erythromycin
B derivatives are given in Table 3.
Erythromycin B 9-oxime shows in the best-ranked solution after Firedock refinement
without predetermined binding sites only interactions with nucleotides: π-σ (violet circles),
and π-Lone pair (light green circles) and π-alkyl (pink circles) (Figure 3). Erythromycin
B 2′-[3-(morpholinomethyl)benzoate] under the same circumstances shows the solution
with the following interactions with nucleotides: π-σ (violet circles), π-alkyl (pink circles),
and carbon-hydrogen bond (light blue circles), as well as unfavourable bumps (red circles)
(Figure 4).
Erythromycin B 2′-[3-(dimethylaminomethyl)benzoate] shows very similar behaviour
regarding present interactions in the best-ranked solution structure after refinement us-
ing Firedock algorithm with the receptor: π-alkyl (pink circles), carbon hydrogen bond
(light-blue circles), and an unfavourable bump (red circle) (Figure 5). 5-Desosaminyl ery-
thronolide B ethyl succinate shows the following interactions with the nucleotides in the
best-ranked solution: π-σ (violet circles), π-alkyl (pink circles), and carbon hydrogen bond
(light-blue circles), as well as an unfavourable bump (red circle) (Figure 6).
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Table 2. Score, area, and ACE (atomic contact energy) of top ten results based on shape complementarity principles for
docking analysis of investigated derivatives of erythromycin B with complex of protein and three domains of 23S rRNA.
Solutions SolutionParameters
Derivatives
EryB 90 EBMMB EBDAMB 5DAEBES d-Ery B
1
Score 7332 7578 7362 6430 7132
Area 886.20 972.00 1012.70 740.40 800.00
ACE −341.11 −477.95 −490.63 −324.01 −337.27
2
Score 7032 7388 7030 6222 6416
Area 839.20 951.20 745.90 739.90 754.20
ACE −339.59 −419.55 −275.08 −467.41 −362.32
3
Score 6640 7376 6980 6162 6296
Area 845.50 896.30 785.80 865.40 900.70
ACE −277.37 −424.72 −376.62 −404.81 −342.87
4
Score 6636 7276 6970 6110 6272
Area 700.10 966.70 827.10 840.20 749.90
ACE −326.43 −462.36 −437.15 −442.39 −264.42
5
Score 6598 6834 6954 6056 6260
Area 896.20 898.30 860.40 727.70 836.30
ACE −408.91 −461.77 −418.69 −365.69 −280.40
6
Score 6556 6830 6904 6000 6254
Area 704.80 814.00 858.30 759.10 701.70
ACE −379.30 −311.01 −431.74 −286.73 −325.53
7
Score 6554 6826 6896 5972 6250
Area 719.30 891.70 816.60 831.00 736.90
ACE −336.11 −334.69 −362.42 −319.28 −386.86
8
Score 6524 6824 6870 5952 6212
Area 802.30 885.40 812.00 716.10 722.80
ACE −464.79 −330.79 −351.92 −351.59 −353.71
9
Score 6500 6726 6868 5896 6190
Area 786.90 754.70 851.10 646.80 670.10
ACE −389.76 −291.68 −349.78 −267.87 −306.69
10
Score 6462 6722 6790 5892 6122
Area 714.60 1011.00 1014.50 693.60 804.90
ACE −372.85 −489.58 −487.56 −183.95 −351.11
The docking results, followed by the refinement, provide a good explanation for
the results of the anti-malarial tests. The highest number of unfavourable interactions
is shown by erythromycin B 2′-[3-(morpholinomethyl)benzoate]; therefore, it is not sur-
prising that this compound does not show any anti-malarial activity (IC50 > 200 µM).
Erythromycin B 9-oxime does not show any unfavourable interactions, different from
others, but it shows only five favourable interactions, the lowest number among the inves-
tigated erythromycin B derivatives. The highest number of favourable interactions was
shown in case of 5-desosaminyl erythronolide B ethyl succinate; therefore, it is in good
correlation with found IC50 value, which is the lowest among the investigated derivatives,
i.e., the highest anti-malarial activity among the tested compounds. Erythromycin B 2′-[3-
(dimethylaminomethyl)benzoate] shows a higher number of favourable interactions (8)
compared to 8-d-erythromycin B (7), but the last derivative shows interaction with more con-
tribution (π-Lone pair); therefore, this is the reason why 8-d-erythromycin B shows better
anti-malarial activity compared to erythromycin B 2′-[3-(dimethylaminomethyl)benzoate].
π-Lone pair is the interaction shared both between 8-d-erythromycin B and erythromycin
B 9-oxime, but because of the higher number of favourable interactions shown by 8-d-
erythromycin B, it shows better anti-malarial activity.
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Table 3. Solution number, global energy, attractive Van der Waals, repulsive van der Waals, and ACE for investigated erythromycin B derivatives with in silico constructed segment of the
exit tunnel from the apicoplast ribosome of P. falciparum.
Rank
Derivatives
eryB9O eryBMB eryBDA eryBD eryB8D
SN GE AVdW RVdW ACE SN GE AVdW RVdW ACE SN GE AVdW RVdW ACE SN GE AVdW RVdW ACE SN GE AVdW RVdW ACE
1 10 −63.18 −23.29 9.23 −22.58 5 −74.06 −28.32 8.97 −24.41 5 −57.60 −23.55 13.89 −21.13 2 −67.89 −25.26 11.31 −24.74 6 −63.40 −26.31 9.46 −20.67
2 9 −60.65 −24.69 9.32 −20.27 3 −55.61 −21.65 7.65 −19.85 4 −52.66 −20.91 14.62 −20.77 1 −52.42 −20.56 9.31 −18.29 1 −61.51 −23.48 8.48 −20.95
3 1 −60.28 −24.59 8.05 −19.29 4 −50.21 −26.49 26.04 −19.84 8 −51.82 −21.02 4.11 −15.61 8 −49.83 −22.88 22.20 −20.92 2 −48.35 −21.82 17.42 −18.82
4 2 −59.82 −23.60 12.36 −21.84 9 −44.94 −18.35 7.22 −15.85 10 −51.58 −28.90 26.43 −20.68 7 −47.89 −23.46 14.09 −16.53 8 −46.70 −20.56 18.10 −19.11
5 8 −53.61 −23.03 16.31 −21.13 7 −44.11 −24.22 27.44 −18.84 6 −48.66 −23.05 16.02 −19.41 3 −45.82 −19.87 8.91 −15.22 9 −45.24 −15.63 3.87 −15.69
6 6 −47.33 −16.88 9.54 −18.68 6 −41.75 −23.33 15.91 −14.88 2 −48.50 −18.58 4.20 −15.64 10 −44.62 −22.38 8.79 −14.04 7 −42.49 −17.24 11.94 −16.47
7 4 −44.88 −16.35 7.59 −16.79 2 −30.70 −25.80 40.54 −17.23 3 −45.67 −22.70 23.01 −19.13 9 −38.29 −17.57 11.63 −14.30 4 −40.76 −19.02 11.57 −15.62
8 7 −42.39 −16.63 9.09 −15.56 10 −29.42 −18.97 19.66 −12.45 7 −41.62 −19.57 13.90 −16.31 5 −38.09 −21.25 25.36 −18.31 3 −33.22 −14.06 6.78 −13.20
9 3 −23.15 −7.92 2.81 −9.12 8 −21.96 −11.50 4.54 −5.58 1 −40.86 −25.65 23.11 −15.79 4 −34.84 −14.83 7.62 −12.25 5 −24.99 −12.77 12.30 −11.45
10 5 −15.07 −9.36 7.03 −4.80 1 −15.89 −27.10 72.48 −21.55 9 −24.27 −8.63 3.70 −9.54 6 −32.26 −20.80 22.81 −13.81 10 −11.66 −22.26 59.71 −16.76
Abbreviations used: eryB9O: erythromycin B 9-oxime, eryBD: 5-desosaminyl erythronolide B ethyl succinate, eryBMB: erythromycin B 2′-[3-(morpholinomethyl)benzoate], eryBDA: erythromycin B 2′-
[3-(dimethylaminomethyl)benzoate], eryB8D: 8-d-erythromycin B, SN: solution number, GE: global energy, AVdW: attractive Van der Waals, RVdW: repulsive Van der Waals, and ACE: atomic contact
energy.
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It can be speculated that the small number of favourable interactions or the presence
of unfavourable interactions is the reason for weak anti-malarial activity of investigated
derivatives of erythromycin B. M lecular docking can also be a good tool for the prediction
of anti-malarial activity f derivatives with previously undetermined anti-malarial activity.
In the future, we will broaden our investigation using both in silico tools and experimental
results.
4. Conclusions
Five derivatives of erythromycin B were synthesised and evaluated for their anti-
malarial activity against multi-drug-resistant K1 strain of P. falciparum. They do not show
significant anti-malarial activity, ranging from 68.6 µM for 5-desosaminyl erythronolide B
ethyl succinate to more than 200 µM for erythromycin B 2′-[3-(morpholinomethyl)benzoate]
and erythromycin B 2′-[3-(dimethylaminomethyl)benzoate]. Performed conformational
search (unconstrained for all and constrained only for erythromycin B 2′-[3-(dimethylamino
methyl)benzoate]) in chloroform gave the most probable folded-out structures which were
used as active conformations for molecular docking. Molecular docking results provided
an explanation for the order of anti-malarial activity amongst the investigated derivatives
of erythromycin B.
Materials 2021, 14, 6980 16 of 17
Author Contributions: Conceptualisation, N.N., S.F., J.B. and B.A.; methodology, N.N., S.F., J.B. and
B.A.; formal analysis, P.K.B., R.N.M. and B.A.; investigation, P.K.B., R.N.M. and B.A.; resources,
B.A.; data curation, P.K.B., R.N.M., N.N., S.F., J.B. and B.A.; writing—original draft preparation,
B.A.; writing—review and editing: P.K.B., R.N.M., N.N., S.F., J.B. and B.A.; visualization, P.K.B.,
R.N.M. and B.A.; supervision, N.N., S.F., J.B. and B.A.; project administration, N.N., S.F., J.B. and
B.A.; funding acquisition, B.A. All authors have read and agreed to the published version of the
manuscript.
Funding: Biljana Arsic wants to thank for the financial support for the work to Ministry of Education,
Science and Technological Development of Republic of Serbia (contract number 451-03-9/2021-
14/200124). Rachael Magwaza thanks Aspen Pharmacare (SA) and National Research Foundation
(grant no.: 107881) for sponsorship.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: All data necessary for understanding of the research are present in
the manuscript. Additional data related to molecular modelling and NMR analyses of synthesised
compounds can be obtained from authors upon the request.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. World Health Organization. Malaria. Available online: https://www.who.int/news-room/fact-sheets/detail/malaria (accessed
on 13 November 2021).
2. Ford, J.M.; Hait, W.N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 1990, 42, 155–199.
[PubMed]
3. Menezes, M.S.; Kirchgatter, K.; Di Santi, S.M.F.; Savalli, C.; Monteiro, F.G.; Paula, G.A.; Ferreira, E.I. In vitro evaluation of
erythromycin in chloroquine resistant Brazilian P. falciparum freshly isolates: Modulation effect and antimalarial activity evidence.
Rev. Inst. Med. Trop. São Paulo 1999, 41, 249–253. [CrossRef]
4. Hofsli, E.; Nissen-Meyer, J. Effect of erythromycin and tumour necrosis factor on the drug resistance of multidrug-resistant cells:
Reversal of drug resistance by erythromycin. Int. J. Cancer 1989, 43, 520–525. [CrossRef]
5. Hofsli, E.; Nissen-Meyer, J. Reversal of multidrug resistance by lipophilic drugs. Cancer Res. 1990, 50, 3997–4002. [PubMed]
6. Robinson, B.L.; Warhurst, D.C. Antimalarial activity of erythromycin. Trans. R. Soc. Trop. Med. Hyg. 1972, 66, 525.
7. Gaillard, T.; Madamet, M.; Tsombeng, F.F.; Dormoi, J. Antibiotics in malaria therapy: Which antibiotics except tetracyclines and
macrolides may be used against malaria? Malar. J. 2016, 15, 556. [CrossRef]
8. Sowunmi, A.; Gbotosho, G.O.; Fateye, B.A.; Adedeji, A.A. Predictors of the failure of treatment with trimethoprim-
sulfamethoxazole in children with uncomplicated, Plasmodium falciparum malaria. Ann. Trop. Med. Parasitol. 2006, 100, 205–211.
[CrossRef] [PubMed]
9. Mermin, J.; Ekwaru, J.P.; Liechty, C.A.; Were, W.; Downing, R.; Ransom, R.; Weidle, P.; Lule, J.; Coutinho, A.; Solberg, P. Effect of
co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected
adults in Uganda: A prospective cohort study. Lancet 2006, 367, 1256–1261. [CrossRef]
10. Manyando, C.; Njunju, E.M.; Mwakazanga, D.; Chongwe, G.; Mkandawire, R.; Champo, D.; Mulenga, M.; De Crop, M.; Claeys, Y.;
Ravinetto, R.M.; et al. Safety of daily co-trimoxazole in pregnancy in an area of changing malaria epidemiology: A phase 3b
randomized controlled clinical trial. PLoS ONE 2014, 9, 96017.
11. Corbett, E.L.; Churchyard, G.J.; Charalambos, S.; Samb, B.; Moloi, V.; Clayton, T.C.; Grant, A.D.; Murray, J.; Hayes, R.J.; De Cock,
K.M. Morbidity and mortality in South African gold miners: Impact of untreated disease due to human immunodeficiency virus.
Clin. Infect. Dis. 2002, 34, 1251–1258. [CrossRef]
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